Advertisement Vyrix enters into agreement with Paladin for exclusive rights of Zertane in Canada - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Vyrix enters into agreement with Paladin for exclusive rights of Zertane in Canada

Vyrix Pharmaceuticals, a subsidiary of Ampio Pharmaceuticals has signed an agreement with Paladin Labs, a Canadian specialty pharmaceutical firm, to provide exclusive rights to market, sell and distribute Zertane (tramadol HCl) in Canada, South Africa, Sub-Saharan Africa and Latin America.

Zertane is an oral drug currently in late-stage development as a proprietary treatment for premature ejaculation, a condition that has a major impact on the quality of life for men and their sexual partners and has showed a favorable efficacy profile in clinical trials.

Vyrix Pharmaceuticals president and chief executive officer Jarrett Disbrow said the company is happy to have Paladin as its first North American partner to commercialize Zertane.

"Our agreement with Paladin is consistent with Vyrix’s global commercialization strategy focused on developing partnerships with established companies that are dominant in key international markets and have a specialty that aligns with Zertane to maximize its visibility," Disbrow said.

"This agreement further broadens the international footprint for Zertane by adding Canada, Africa and Latin America to our existing partnerships in South Korea and Brazil where the pending Australian TGA approval of Zertane should enable product registration in the near-term.

"We continue ongoing discussions with additional potential partners, which we believe will position Zertane to gain maximum international exposure and drive more value than aligning with a single worldwide partner."
According to the company, Zertane is to be taken 1-2 hours before sexual activity as needed and is not required to be taken on a daily basis.

There has not yet been an oral drug approved in the US for the treatment of premature ejaculation.
The deal offers an upfront payment, approval and revenue-based milestone payments and an ongoing double-digit royalty stream to Vyrix.

The two firms will collaborate to apply for Health Canada approval for Zertane to allow near-term registration in Canada with registrations in other countries in the Territory to follow.